Back to Search Start Over

It takes two peroxisome proliferator-activated receptors (PPAR-β/δ and PPAR-γ) to tango idiopathic pulmonary fibrosis

Authors :
Eistine Boateng
Rocio Bonilla-Martinez
Barbara Ahlemeyer
Vannuruswamy Garikapati
Mohammad Rashedul Alam
Omelyan Trompak
Gani Oruqaj
Natalia El-Merhie
Michael Seimetz
Clemens Ruppert
Andreas Günther
Bernhard Spengler
Srikanth Karnati
Eveline Baumgart-Vogt
Source :
Respiratory Research, Vol 25, Iss 1, Pp 1-19 (2024)
Publication Year :
2024
Publisher :
BMC, 2024.

Abstract

Abstract Background Idiopathic pulmonary fibrosis (IPF) is characterized by aberrant lung epithelial phenotypes, fibroblast activation, and increased extracellular matrix deposition. Transforming growth factor-beta (TGF-β)1-induced Smad signaling and downregulation of peroxisomal genes are involved in the pathogenesis and can be inhibited by peroxisome proliferator-activated receptor (PPAR)-α activation. However, the three PPARs, that is PPAR-α, PPAR-β/δ, and PPAR-γ, are known to interact in a complex crosstalk. Methods To mimic the pathogenesis of lung fibrosis, primary lung fibroblasts from control and IPF patients with comparable levels of all three PPARs were treated with TGF-β1 for 24 h, followed by the addition of PPAR ligands either alone or in combination for another 24 h. Fibrosis markers (intra- and extracellular collagen levels, expression and activity of matrix metalloproteinases) and peroxisomal biogenesis and metabolism (gene expression of peroxisomal biogenesis and matrix proteins, protein levels of PEX13 and catalase, targeted and untargeted lipidomic profiles) were analyzed after TGF-β1 treatment and the effects of the PPAR ligands were investigated. Results TGF-β1 induced the expected phenotype; e.g. it increased the intra- and extracellular collagen levels and decreased peroxisomal biogenesis and metabolism. Agonists of different PPARs reversed TGF-β1-induced fibrosis even when given 24 h after TGF-β1. The effects included the reversals of (1) the increase in collagen production by repressing COL1A2 promoter activity (through PPAR-β/δ activation); (2) the reduced activity of matrix metalloproteinases (through PPAR-β/δ activation); (3) the decrease in peroxisomal biogenesis and lipid metabolism (through PPAR-γ activation); and (4) the decrease in catalase protein levels in control (through PPAR-γ activation) and IPF (through a combined activation of PPAR-β/δ and PPAR-γ) fibroblasts. Further experiments to explore the role of catalase showed that an overexpression of catalase protein reduced collagen production. Additionally, the beneficial effect of PPAR-γ but not of PPAR-β/δ activation on collagen synthesis depended on catalase activity and was thus redox-sensitive. Conclusion Our data provide evidence that IPF patients may benefit from a combined activation of PPAR-β/δ and PPAR-γ.

Details

Language :
English
ISSN :
1465993X
Volume :
25
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Respiratory Research
Publication Type :
Academic Journal
Accession number :
edsdoj.497c1b77bedd4f42ab38ca4d615984cc
Document Type :
article
Full Text :
https://doi.org/10.1186/s12931-024-02935-7